Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
89%
Hematopoietic Cell Transplantation
57%
Graft-versus-host Disease (GvHD)
56%
Marrow
48%
Canine
46%
Nonmyeloablative
44%
Total Body Irradiation
37%
Engraftment
35%
Immunosuppression
33%
Marrow Transplantation
32%
Myeloablative Conditioning
30%
Transplantation
30%
Hematopoietic Stem Cell Transplantation
26%
Mycophenolate Mofetil
24%
Dog Leukocyte Antigen
24%
Mixed Hematopoietic chimerism
21%
Donor chimerism
19%
High Dose
19%
Cyclosporine
18%
Cyclophosphamide
18%
Conditioning Regimen
17%
Allogeneic
17%
Hematological Malignancies
17%
Multiple Sclerosis
15%
Post-grafting
15%
T Cells
14%
Donor Lymphocyte Infusion
14%
Littermate
14%
Overall Survival
14%
Chimera
14%
Adoptive Immunotherapy
14%
High-dose Immunosuppressive Therapy
14%
Relapsing-remitting multiple Sclerosis
14%
Fludarabine
13%
Hematopoietic Cells
13%
Graft-versus-leukemia Effect
12%
Graft Rejection
12%
Non-relapse Mortality
12%
Allograft
12%
Human Leukocyte Antigen
12%
Canine Model
12%
Granulocyte Colony-stimulating Factor (G-CSF)
12%
Unrelated Donor
11%
Cell Grafting
11%
Cytotoxic T Lymphocytes
11%
Mixed chimerism
11%
Systemic Sclerosis
11%
Progression-free Survival
11%
Hematopoietic chimerism
10%
Older Patients
10%
Immunology and Microbiology
Hematopoietic Cell
100%
Cell Transplantation
82%
Conditioning
42%
Engraftment
41%
Immunosuppression
33%
Graft-Versus-Host Disease
28%
Leukocyte Antigen
27%
Drug Megadose
26%
Allograft
24%
Mycophenolate Mofetil
24%
Cyclophosphamide
22%
CD34
21%
T Cell
19%
Ciclosporin
18%
Hematopoietic Stem Cell Transplantation
16%
Canine Model
15%
Overall Survival
14%
Lymphocyte
14%
Systemic Scleroderma
13%
Chronic Graft Versus Host Disease
12%
Granulocyte Colony-Stimulating Factor
12%
Bone Marrow Transplantation
11%
Cytotoxic T Cell
11%
Nonmyeloablative Stem Cell Transplantation
11%
Autologous Stem Cell Transplantation
11%
Acute Graft Versus Host Disease
11%
Adoptive Immunotherapy
10%
Aplastic Anemia
10%
Graft Versus Tumor Effect
10%
Low Drug Dose
10%
Scleroderma
10%
Peripheral Blood Mononuclear Cell
9%
Stem Cell
9%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Immune Tolerance
8%
Dendritic Cell
8%
Anti-Thymocyte Globulin
8%
CD3 Antigen
8%
Minor Histocompatibility Antigen
8%
Event Free Survival
8%
Comorbidity
7%
Human Leukocyte Antigen
7%
Neutrophil
7%
Platelet
7%
Immunosuppressive Therapy
7%
Platelet Count
6%
CD14
6%
Stem Cell Transplantation
6%
Progression Free Survival
6%
Lymph Node
5%
Medicine and Dentistry
Hematopoietic Cell
81%
Cell Transplantation
67%
Diseases
23%
Immunosuppressive Treatment
20%
Conditioning
18%
Cyclophosphamide
17%
Drug Megadose
16%
Hematologic Malignancy
15%
Nonmyeloablative Conditioning
15%
Hematopoietic Stem Cell Transplantation
14%
Multiple Sclerosis
14%
Aplastic Anemia
14%
Systemic Scleroderma
13%
Whole Body Radiation
12%
Engraftment
12%
Overall Survival
12%
Nonmyeloablative Stem Cell Transplantation
11%
Fludarabine
11%
Scleroderma
10%
Chronic Graft Versus Host Disease
9%
Allograft
9%
Graft Versus Host Reaction
8%
T Cell
8%
Bone Marrow Transplantation
8%
Multiple Myeloma
8%
Progression Free Survival
8%
Busulfan
8%
Stem Cell
8%
Graft Versus Tumor Effect
8%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Autologous Hematopoietic Stem Cell Transplantation
7%
Autologous Stem Cell Transplantation
7%
Acute Lymphoblastic Leukemia
7%
Cytotoxic Chemotherapy
7%
Mycophenolate Mofetil
7%
Event Free Survival
6%
Cyclosporine
6%
Human Leukocyte Antigen
6%
Myeloablative Conditioning
6%
Graft Rejection
5%
Polycythemia vera
5%
Myeloid metaplasia
5%
Essential Thrombocythaemia
5%
Allogenic Bone Marrow Transplantation
5%
Comorbidity
5%